文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Loberamisal治疗急性缺血性卒中:LAIS随机临床试验

Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-09-10

LAIS为多中心双盲随机安慰剂对照3期试验,纳入中国32家医院998例发病48小时内急性缺血性卒中患者。静脉loberamisal 40 mg每日一次连用10天,90天mRS 0-1比例69.7% vs 56.3%(RR 1.24,95%CI 1.12-1.36)。

要点

  • 发病48小时内急性缺血性卒中患者静脉loberamisal可提高90天功能独立比例。
  • 90天mRS 0-1:loberamisal组69.7%,安慰剂组56.3%,风险差13.28%。
  • 不良事件与严重不良事件两组相近,全因死亡率1.2% vs 2.0%。

核心结论

  • 发病48小时内急性缺血性卒中患者静脉loberamisal较安慰剂提高90天达到mRS 0-1的比例。
  • 需进一步研究验证结果并明确获益是否可扩展至更广泛患者人群。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照3期临床试验,中国32家医院开展。
  • 纳入18至80岁急性缺血性卒中、基线NIHSS 7-20、病前mRS≤1、发病48小时内患者。
  • 998例随机,997例接受至少1剂并纳入主要分析(loberamisal组502例,安慰剂组495例)。
  • 干预为静脉loberamisal 40 mg或匹配安慰剂每日一次连续10天,联合标准卒中治疗。

主要发现

  • 90天mRS 0-1:loberamisal组350例(69.7%),安慰剂组279例(56.3%)(RR 1.24;95%CI 1.12-1.36;风险差13.28%;95%CI 7.24%-19.32%)。
  • 不良事件:loberamisal组441例(87.8%),安慰剂组439例(88.7%)。
  • 严重不良事件:loberamisal组43例(8.6%),安慰剂组53例(10.7%)。
  • 全因死亡:loberamisal组6例(1.2%),安慰剂组10例(2.0%)。

临床怎么用

  • 对发病48小时内、NIHSS 7-20、病前无残疾的急性缺血性卒中患者,可考虑静脉loberamisal 40 mg每日一次连用10天作为标准治疗外的附加治疗。
  • 治疗决策需结合本研究人群特征,超出发病48小时或NIHSS范围者证据不足。

局限性

  • 研究仅在中国32家医院开展,人群代表性有限。
  • 随访至90天,缺乏更长时程疗效与安全性数据。
  • 作者指出需进一步研究验证结果并明确获益是否可扩展至更广泛人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effective neuroprotective and neuroreparative therapies for acute ischemic stroke remain limited. Loberamisal is a small-molecule compound that dually targets the postsynaptic density 95 (PSD-95) pathway and α2 γ-aminobutyric acid type α (α2-GABAA) receptor. OBJECTIVE: To evaluate the efficacy and safety of intravenous loberamisal for improving functional outcomes in patients with acute ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: The Loberamisal for Acute Ischemic Stroke (LAIS) trial was a multicenter, double-blind, randomized, placebo-controlled phase 3 clinical trial conducted at 32 hospitals in China. Adults aged 18 to 80 years with acute ischemic stroke, a baseline National Institutes of Health Stroke Scale score of 7 to 20, and no prestroke disability (modified Rankin Scale score, ≤1) who presented within 48 hours of symptom onset were enrolled between July 24, 2024, and December 7, 2024, with final follow-up on April 8, 2025. INTERVENTIONS: Participants were randomly assigned (1:1) to receive intravenous loberamisal (40 mg) or matching placebo once daily for 10 consecutive days, in addition to standard stroke care. MAIN OUTCOMES AND MEASURES: The primary outcome was achieving a full functional outcome at 90 days, defined as a modified Rankin Scale (mRS) score of 0 to 1. Safety outcomes included adverse events, serious adverse events, and mortality. RESULTS: Among 998 randomized participants, 997 received at least 1 dose of the study drug and were included in the primary analysis (502 in the loberamisal group and 495 in the placebo group). The median age was 64 years (IQR, 57-71), 336 participants (33.7%) were women, and the median baseline NIHSS score was 8 (IQR, 7-9). At 90 days, 350 participants (69.7%) in the loberamisal group achieved an mRS score of 0 to 1 compared with 279 (56.3%) in the placebo group (relative risk, 1.24; 95% CI, 1.12-1.36; risk difference, 13.28%; 95% CI, 7.24%-19.32%). Adverse events occurred in 441 participants (87.8%) in the loberamisal group and 439 (88.7%) in the placebo group. Serious adverse events occurred in 43 participants (8.6%) in the loberamisal group and 53 (10.7%) in the placebo group. All-cause mortality occurred in 6 participants (1.2%) in the loberamisal group and 10 (2.0%) in the placebo group. CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke treated within 48 hours of symptom onset, intravenous loberamisal, compared with placebo, resulted in a higher proportion of patients achieving full functional outcomes at 90 days. Further studies are needed to validate these findings and establish whether the benefits could extend to a broader patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06517173.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Li S, Feng B, He D, et al. Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial. JAMA. 2026. PMID: 42721021. doi:10.1001/jama.2026.16557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。